Executive SummarySchein’s $240 million acquisition of Marsam reflects the type of one-stop shopping and product breadth drug companies envisioned by drug companies when they went prospecting for generic businesses.
You may also be interested in...
Celltrion has unveiled plans to construct a biologics plant in Wuhan, China, as well as setting up a direct sales network in the country, as part of its wider global strategy that also involves launching a new biosimilar every year to 2030.
Often dismissed as a meeting of the global elite, Davos is nevertheless a chance for biopharma leaders to take part in ‘big picture’ debates
An EU pilot project will assess whether there is sufficient demand from companies to obtain simultaneous scientific advice from EU national competent authorities.